Short answer
As of November 2026, most peptides sold through telehealth cannot be advertised as products on Meta: its Drugs and Pharmaceuticals policy bars ads for substances Meta judges unsafe and lets only LegitScript-certified, authorized advertisers promote prescription drugs. MedScale Health, a paid ads agency for US telehealth brands and clinics, runs the consult and the clinic for peptide clients and never the compound itself. Most telehealth peptides, BPC-157 included, are not FDA-approved.
Can peptide brands advertise on Meta at all?
Most peptide brands asking this question want to hear that the right creative approach opens the channel. MedScale works with telehealth brands and clinics, and giving that answer would be dishonest: for the majority of peptides sold through telehealth, Meta is closed to the product rather than difficult, and the constraint is the product rather than the advertising.
Peptides are a different situation from GLP-1, where the category is permitted and the discipline is in how creative is structured. In peptides, the underlying regulatory status of the substance is usually what blocks the channel, and no amount of copywriting changes it.
Why does Meta's drugs policy catch peptides?
Meta's Drugs and Pharmaceuticals policy says advertisers can't run ads that promote the sale or use of illicit or recreational drugs, or other unsafe substances, products or supplements, as determined by Meta at its sole discretion. It allows prescription drug ads only from advertisers actively certified with LegitScript and authorized by Meta. Peptides commonly sold in telehealth meet one or both conditions, because many are not approved for human therapeutic use, several are sold under research framing, and those dispensed through prescribers are prescription products.
A peptide ad's route into a violation therefore does not depend on how aggressive the creative is. A restrained, factual ad for a product the platform treats as unapproved is still an ad for a product the platform treats as unapproved. MedScale checks a substance's status before any creative is written, because the status decides the outcome.
Can you advertise BPC-157 on Meta in October 2026?
No. FDA's page on bulk drug substances that may present significant safety risks, current as of April 22, 2026, lists BPC-157 under "nominated but withdrawn": substances previously in Category 2 whose nominators withdrew them. At its July 23-24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend BPC-157 for the 503A bulks list, alongside KPV, TB-500, MOTS-c, Epitalon and Semax.
The committee's vote is a non-binding recommendation. On October 14, 2026, FDA sent a notice titled "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Information and Regulatory Affairs for review. Its text is not public. As of October 23, 2026, BPC-157 is not on the 503A bulks list and is not FDA-approved, so product ads stay closed on Meta, Google and TikTok. MedScale does not advertise BPC-157 itself for any client.
What changed for BPC-157 ads in November 2026?
On October 30, 2026, HHS said it does not intend to take enforcement action against 503A pharmacies, federal facilities or licensed physicians that compound BPC-157, TB-500, Epitalon, Semax, KPV or MOTS-c under its conditions. On November 2, 2026, LegitScript said offering one of these peptides "should not, by itself, prevent a merchant from achieving certification" when the offering meets those conditions. Meta's side has not moved: its Drugs and Pharmaceuticals policy still bars ads for "unsafe substances, products or supplements, as determined by Meta at its sole discretion," and LegitScript says its "certification does not guarantee access" to ad platforms or payment providers. MedScale Health keeps peptide ads on the consult until Meta publishes a change.
Does research-use framing help peptide ads on Meta?
A common workaround is to describe peptides as research chemicals not for human consumption. As an advertising strategy the research label is close to self-defeating: it states explicitly that the product is not approved for the use the audience is buying it for, and it creates a mismatch between the ad and the actual funnel.
Platforms assess what the funnel does rather than what the disclaimer says. A research framing paired with a consumer purchase flow reads as misrepresentation, which is a second policy problem stacked on the first. MedScale does not run ads into research-framed peptide funnels for that reason.
What can a peptide clinic run on Meta?
Some brands do run paid social successfully, and the pattern is consistent: they advertise something other than the peptide.
- Advertising the clinical consultation or the broader program, where peptides are one possible outcome rather than the offer.
- Advertising an adjacent approved category, with peptides discovered later in the relationship.
- Brand and category education that does not promote a specific restricted substance.
Each route is a genuine narrowing of the message and needs a destination page that matches. An ad about a consultation that lands on a peptide product page will be assessed on the page, so MedScale builds the consult landing page alongside the ad.
LegitScript drew the same line for certified businesses on September 22, 2026: offering, promoting or advertising a peptide that is not permissible under current FDA rules, such as BPC-157, TB-500 or retatrutide, is a violation, and partnering with a separate entity that prescribes or dispenses it is no workaround. Education that encourages use of an unapproved drug counts as promotion, whether or not the business sells the product.
LegitScript narrowed that line on November 2, 2026 for the six peptides in HHS's October 30 policy. Other peptides, including retatrutide, and combinations "such as BPC-157 with TB-500 or semaglutide" still fall outside it.
What happens when a peptide ad runs on Meta anyway?
The expensive version of the lesson is testing peptide creative until the account is restricted, then discovering that the restriction affects linked assets in the same Business Manager, including the ones supporting product lines that were compliant.
MedScale's advice is to keep business assets organized and clean, never to keep advertising a prohibited product. MedScale runs peptide clinics on a consult-led structure, where the ad and the page sell the visit and never name a compound.
Common questions
- 01Can I advertise peptides if a licensed clinician prescribes them?
- Not as a product. A prescriber relationship addresses the clinical question but not the platform policy question, since restrictions on promoting prescription and unapproved products apply to the advertiser regardless. Prescription involvement can also bring certification requirements into scope on top of the existing restrictions.
- 02What happens if I run peptide ads anyway?
- Expect disapprovals and, with repetition, account restriction, and enforcement can extend to linked assets in the same Business Manager. The risk that matters most is not the rejected ad but the exposure of compliant product lines sharing the same business structure.
- 03Is it different if I only mention peptides on the landing page?
- No, because Meta reviews the destination as part of the ad. Moving the restricted content from the creative to the page keeps it inside the scope of review, and page-level violations are a common cause of disapproval in this category.
- 04Did the July 2026 FDA advisory vote make BPC-157 advertisable on Meta?
- No. The committee's 8 to 6 vote to recommend BPC-157 for the 503A bulks list is not binding on FDA. On October 14, 2026, FDA sent a notice titled "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Information and Regulatory Affairs for review. Its text is not public. As of October 23, 2026, BPC-157 is not on the 503A bulks list and is not FDA-approved, so product ads stay closed on Meta, Google and TikTok. Meta's policy on unsafe and unapproved substances still applies. Update, November 9, 2026: HHS published the policy on October 30, 2026 (Federal Register 2026-22192) as an enforcement discretion policy, not an approval, and Meta, Google and TikTok had not changed their ad rules, so MedScale Health still runs the consult on Meta.
- 05Are any peptides straightforwardly advertisable?
- Very few. Status varies by substance and by jurisdiction, and a small number sit in a materially different position from the research-framed majority. Each substance needs to be assessed individually with regulatory advice rather than treated as part of a single category.
- 06Can a LegitScript-certified telehealth brand advertise BPC-157 on Meta now?
- Not yet, as of November 3, 2026. LegitScript can now certify a business whose BPC-157 offering meets HHS's October 30 conditions, but Meta still decides what it treats as an unsafe substance and has published no change. MedScale runs the consult and the clinic, and checks Meta's policy page before any peptide campaign.
Sources
- 01Meta Advertising Standards: Drugs and Pharmaceuticalschecked October 5, 2026
- 02Meta Advertising Standards: Introductionchecked October 5, 2026
- 03FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of Apr 22, 2026)checked October 5, 2026
- 04FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committeechecked October 5, 2026
- 05NCPA (Jul 31, 2026): FDA advisory committee nominates six peptides pharmacies can compoundchecked October 5, 2026
- 06LegitScript (Sep 22, 2026): The Peptide Boom, why so many popular products are still off-limitschecked October 12, 2026
- 07Reginfo.gov: OIRA regulatory review list, FDA notice 0910-ZD94, Interim Access Policy for Compounding Using Certain Peptides (received Oct 14, 2026)checked October 23, 2026
- 08Federal Register 2026-22192 (Oct 30, 2026): HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (RIN 0910-ZD94)checked November 3, 2026
- 09HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (PDF)checked November 3, 2026
- 10LegitScript (Nov 2, 2026): HHS's Peptide Compounding Policy, what healthcare businesses need to knowchecked November 3, 2026
- 11Federal Register 2026-22192 (Oct 30, 2026): HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (rechecked Nov 9, 2026)checked November 9, 2026
- 12Google Ads policy: Unapproved substances (rechecked Nov 9, 2026)checked November 9, 2026
- 13TikTok Ads policy: Healthcare and Pharmaceuticals (last updated September 2026, rechecked Nov 9, 2026)checked November 9, 2026
- 14Meta Business Help Center: About Meta's Prescription Drugs advertising policy (rechecked Nov 9, 2026)checked November 9, 2026
Related answers
Why Does Google Ads Reject Peptide Advertising?
As of November 2026, Google prohibits promoting unapproved substances and restricts prescription drug promotion to certified advertisers, and most telehealth peptides fall into the first group rather than the second. MedScale Health, a paid ads agency for US telehealth brands and clinics, runs a consult-only paid structure for peptide clinics that never names a compound, because certification does not lift the prohibition. Peptide brands often pursue certification expecting it to open the category, when certification solves a different problem.
Reviewed November 9, 2026
How Do You Market Peptides When Product Ads Are Closed?
As of November 2026, a peptide clinic markets the consult, not the compound: Meta and Google reject ads that sell most peptides, but ads and a landing page for the clinic visit, the clinician and the lab work, with no compound named, still run. MedScale Health, a paid ads agency for US telehealth brands and clinics, runs that consult-led paid structure. Organic search, email and practitioner referral matter too. MedScale runs organic search and AEO, and every channel lands in the same report.
Reviewed November 9, 2026
Research Peptides vs Prescribed Peptides: Which Carries More Advertising Risk?
As of October 2026, selling peptides as research chemicals does not reduce advertising risk but relocates it, because a not-for-human-consumption label on a consumer funnel is a mismatch platforms treat as misrepresentation. MedScale Health, a paid ads agency for US telehealth brands and clinics, considers the prescribed route the more defensible position commercially as well as legally, though it is the more constrained one.
Reviewed November 3, 2026
Can You Advertise BPC-157, and What Does the FDA Status Mean?
As of November 2026, BPC-157 is not FDA-approved and cannot be advertised as a product on Google or Meta. MedScale Health, a paid ads agency for US telehealth brands and clinics, runs the consult for peptide clinics, never the compound. FDA's compounding advisory committee voted 8 to 6 in July 2026 to recommend BPC-157 for the 503A bulks list, but the vote is non-binding, and the peptide compounding notice FDA sent for White House review on October 14, 2026 was published by HHS on October 30 as an enforcement discretion policy, not an approval; Meta, Google and TikTok kept their ad rules.
Reviewed November 9, 2026
Last reviewed November 9, 2026. Platform policies change often; we re-verify every answer quarterly.